Asia Pacific Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Country and Growth Forecast, 2022 - 2028

The Asia Pacific Atopic Dermatitis Drugs Market should witness market growth of 10.1% CAGR during the forecast period (2022-2028).

The atopic dermatitis market is anticipated to grow significantly during the projected period due to the quick development of novel pipeline medications that are anticipated to increase the market's size. Additionally, the expansion of the atopic dermatitis sector and the rise in the demand for novel biologics and product approvals are both expected to support the market's expansion.

The increasing incidence of atopic dermatitis and favorable reimbursement policies in developing nations are additional factors anticipated to fuel market expansion. Additionally, it is anticipated that increased government efforts to provide better and more economical care as well as increased awareness of the disease's treatment options will have an impact on the market for atopic dermatitis drugs.

Atopic dermatitis, which first manifested in youth, might also get worse over time. Additionally, the issue is a huge one in emerging nations. The condition exhibits a great deal of variation in terms of clinical seriousness, illness severity, tenacity, response to treatment, and inventiveness on both sides. Reducing skin irritation, along with pruritus and flare anticipation, is a key goal of drug-based infection treatment.

Over the past few decades, the frequency of atopic dermatitis has increased in Asian nations, just like it has elsewhere in the world. This increased frequency in Asian nations has been linked to a number of developments, including rapid urbanization, a move toward more westernized lifestyles, and higher living and educational standards. It is crucial to comprehend the rising disease load in Asian nations as well as the variations among them in terms of epidemiology, diagnostic standards, management, quality of life, and financial burden.

The China market dominated the Asia Pacific Atopic Dermatitis Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,508.9 million by 2028. The Japan market is estimated to grow a CAGR of 9.5% during (2022-2028). Additionally, The India market would experience a CAGR of 10.8% during (2022-2028).

Based on Route of Administration, the market is segmented into Injectable, Oral and Topical. Based on Class, the market is segmented into Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.

Scope of the Study

By Route of Administration

• Injectable
• Oral
• Topical

By Class

• Biologics
• Calcineurin Inhibitors
• Corticosteroids
• PDE4 Inhibitors
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Pfizer Inc.
• Sanofi SA
• AbbVie Inc.
• Galderma S.A.
• Eli Lilly and Company
• Leo Pharma A/S
• Regeneron Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Novartis AG
• Incyte Corporation

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free